Inherited and acquired disorders of platelet function

Transfusion Medicine and Hemotherapy

Volumn 34, Issue 1, 2007, Pages 6-19

  Jurk, K ^a   Kehrel, B E ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Bleeding; Platelet disorders; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; ASCORBIC ACID; CELL ADHESION MOLECULE; DESMOPRESSIN; DIPYRIDAMOLE; FUROSEMIDE; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN IX; GLYCOPROTEIN V; HEMOSTATIC AGENT; IBUPROFEN; ICOSAPENTAENOIC ACID; INDOMETACIN; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE C BETA2; PHOSPHOLIPID; PROCOAGULANT; PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOSPONDIN 1; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE LEUKEMIA; AFIBRINOGENAEMIA; ASCORBIC ACID DEFICIENCY; AUTOSOMAL RECESSIVE DISORDER; BERNARD SOULIER DISEASE; BLEEDING; BLOOD CLOT RETRACTION; BLOOD DISEASE; CALCIUM MOBILIZATION; CELL GRANULE; CLINICAL FEATURE; DENSE BODY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIETARY INTAKE; DISSEMINATED INTRAVASCULAR CLOTTING; DYSFIBRINOGENAEMIA; DYSMEGAKARYOCYTOPOIESIS; EHLERS DANLOS SYNDROME; FAMILY HISTORY; FISH; FLOW CYTOMETRY; GLANZMANN DISEASE; HUMAN; INJURY; LABORATORY DIAGNOSIS; LEUKOCYTE; LIVER DISEASE; MYELOPROLIFERATIVE DISORDER; PARTICLE SIZE; PHYSICAL EXAMINATION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; QUEBEC PLATELET DISORDER; REVIEW; SCOTT SYNDROME; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEPSIS; SEROTONIN RELEASE; SIGNAL TRANSDUCTION; STORAGE POOL DISEASE; STORMORKEN SYNDROME; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UREMIA; VON WILLEBRAND DISEASE;

EID: 33846585461     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098178     Document Type: Review

References (125)

1. Ruggeri ZM: Mechanisms of shear-induced platelet adhesion and aggregation. Thromb Haemost 1993;70:119-123.
2. Jurk K, Clemetson KJ, de Groot PG, Brodde MF, Steiner M, Savion N, Varon D, Sixma JJ, Van Aken H, Kehrel BE: Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J 2003;17:1490-1492.
3. Lam SC, Plow EF, D'Souza SE, Cheresh DA, Frelinger AL, III, Ginsberg MH: Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem 1989;264:3742-3749.
4. Hemler ME, Crouse C, Takada Y, Sonnenberg A: Multiple very late antigen (VLA) heterodimers on platelets. Evidence for distinct VLA-2, VLA-5 (fibronectin receptor), and VLA-6 structures. J Biol Chem 1988;263:7660-7665.
5. Bithell TC, Parekh SJ, Strong RR: Platelet-function studies in the Bernard-Soulier syndrome. Ann N Y Acad Sci 1972;201:145-160.
6. Howard MA, Hutton RA, Hardisty RM: Hereditary giant platelet syndrome: a disorder of a new aspect of platelet function. Br Med J 1973;2:586-588.
7. Nurden AT, Combrie R, Claeyssens S, Nurden P: Heterozygotes in the Bernard-Soulier syndrome do not necessarily have giant platelets or thrombocytopenia. Br J Haematol 2003;120:716-717.
8. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC: Bernard-Soulier syndrome. Blood 1998;91:4397-4418.
9. Kahn ML, Diacovo TG, Bainton DF, Lanza F, Trejo J, Coughlin SR: Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and do not exhibit a Bernard-Soulier phenotype. Blood 1999;94:4112-4121.
10. Ozelo MC, Svirin P, Larina L: Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 2005;84:816-822.
11. Sadler JE: New concepts in von Willebrand disease. Annu Rev Med 2005;56:173-191.
12. Sadler JE, for the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis: A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520-525.
13. Miller JL, Castella A: Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood 1982;60:790-794.
14. Mannucci PM: Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-694.
15. Auger JM, Kuijpers MJ, Senis YA, Watson SP, Heemskerk JW: Adhesion of human and mouse platelets to collagen under shear: a unifying model. FASEB J 2005;19:825-827.
16. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ: Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985;318:470-472.
17. Kehrel B, Balleisen L, Kokott R, Mesters R, Stenzinger W, Clemetson KJ, van de Loo J: Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 1988;71:1074-1078.
18. Arai M, Yamamoto N, Moroi M, Akamatsu N, Fukutake K, Tanoue K: Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol 1995;89:124-130.
19. Moroi M, Jung SM, Okuma M, Shinmyozu K: A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989;84:1440-1445.
20. Kehrel B, Wierwille S, Clemetson KJ, Anders O, Steiner M, Knight CG, Farndale RW, Okuma M, Barnes MJ: Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood 1998;91:491-499.
21. Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H: A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 1987;69:1712-1720.
22. Ichinohe T, Takayama H, Ezumi Y, Yanagi S, Yamamura H, Okuma M: Cyclic AMP-insensitive activation of c-Src and Syk protein-tyrosine kinases through platelet membrane glycoprotein VI. J Biol Chem 1995;270:28029-28036.
23. Estes JW: Platelet abnormalities in heritable disorders of connective tissue. Ann N Y Acad Sci 1972;201:445-450.
24. Casonato A, Pontara E, Vertolli UP, Steffan A, Durante C, De Marco L, Sartorello F, Girolami A: Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding. Clin Appl Thromb Hemost 2001;7:81-86.
25. Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS: Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12.
26. Fabris F, Casonato A, Grazia dB, De Marco L, Girolami A: Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 1986;63:75-83.
27. Takahashi H, Nagayama R, Hattori A, Shibata A: Platelet aggregation induced by DDAVP in platelet-type von Willebrand's disease. N Engl J Med 1984;310:722-723.
28. Weinstein M, Ware JA, Troll J, Salzman E: Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. Blood 1988;71:1648-1655.
29. Meschengieser S, Blanco A, Woods A, Maugeri N, Fernandez J, Dupont J, Lazzari MA: Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders. Thromb Res 1987;48:311-319.
30. Yoshida K, Tobe S, Kawata M, Yamaguchi M: Acquired and reversible von Willebrand disease with high shear stress aortic valve stenosis. Ann Thorac Surg 2006;81:490-494.
31. Sloand EM, Sloand JA, Prodouz K, Klein HG, Yu MW, Harvath L, Fricke W: Reduction of platelet glycoprotein Ib in uraemia. Br J Haematol 1991;77:375-381.
32. Gawaz MP, Ward RA: Effects of hemodialysis on platelet-derived thrombospondin. Kidney Int 1991;40:257-265.
33. Sohal AS, Gangji AS, Crowther MA, Treleaven D: Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 2006;118:417-422.
34. Woods VL Jr, Oh EH, Mason D, McMillan R: Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood 1984;63:368-375.
35. Deckmyn H, Chew SL, Vermylen J: Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction. Thromb Haemost 1990;64:74-79.
36. Mohri H, Tanabe J, Ohtsuka M, Yoshida M, Motomura S, Nishida S, Fujimura Y, Okubo T: Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor. Blood Coagul Fibrinolysis 1995;6:561-566.
37. Berndt MC, Kabral A, Grimsley P, Watson N, Robertson TI, Bradstock KF: An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol 1988;68:97-101.
38. Johnson GJ, Holloway DE, Hutton SW, Duane WC: Platelet function in scurvy and experimental human vitamin C deficiency. Thromb Res 1981;24:85-93.
39. Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo NC, Ghiggeri GM, Ravazzolo R, Savino M, Del Vecchio M, d'Apolito M, Iolascon A, Zelante LL, Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M, Glucksman MJ, Aliprandis E, Bizzaro N, Desnick RJ, Martignetti JA: Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet 2000;26:103-105.
40. Weiss HJ, Turitto VT, Baumgartner HR: Further evidence that glycoprotein IIb-IIIa mediates platelet spreading on subendothelium. Thromb Haemost 1991;65:202-205.
41. French DL, Seligsohn U: Platelet glycoprotein IIb/IIIa receptors and Glanzmann's thrombasthenia. Arterioscler Thromb Vasc Biol 2000;20:607-610.
42. Poon MC, D'Oiron R, Von Depka M, Khair K, Negrier C, Karafoulidou A, Huth-Kuehne A, Morfini M: Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004;2:1096-1103.
43. Asselta R, Duga S, Tenchini ML: The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006;4:2115-2129.
44. Weiss HJ, Rogers J: Fibrinogen and platelets in the primary arrest of bleeding. Studies in two patients with congenital afibrinogenemia. N Engl J Med 1971;285:369-374.
45. Lane DA, Scully MF, Thomas DP, Kakkar VV, Woolf IL, Williams R: Acquired dysfibrinogenaemia in acute and chronic liver disease. Br J Haematol 1977;35:301-308.
46. Dawson NA, Barr CF, Alving BM: Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. Am J Med 1985;78:682-686.
47. Cransac M, Carles J, Bernard PH, Malavialle P, Freyburger G, Winnock S, Saric J: Heterozygous protein C deficiency and dysfibrinogenemia acquired by liver transplantation. Transpl Int 1995;8:307-311.
48. Mori T, Murata M, Wakui M, Muto A, Ishida A, Tanosaki R, Okamoto S, Ikeda Y: Acquired dysfibrinogenemia following allogeneic bone marrow transplantation. Am J Hematol 1997;56:294-295.
49. Levi M, ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592.
50. Solum NO, Rigollot C, Budzynski AZ, Marder VJ: A quantitative evaluation of the inhibition of platelet aggregation by low molecular weight degradation products of fibrinogen. Br J Haematol 1973;24:419-434.
51. Yufu Y, Hashimoto M, Muta K, Ideguchi H, Nishimura J, Nawata H: Abnormality of platelet membrane glycoprotein GPIIb in a myelodysplastic syndrome with 3q inversion presenting with marked dysmegakaryopoiesis. Acta Haematol 1990;83:107-110.
52. Chong BH, Ho SJ: Autoimmune thrombocytopenia. J Thromb Haemost 2005;3:1763-1772.
53. DiMinno G, Coraggio F, Cerbone AM, Capitanio AM, Manzo C, Spina M, Scarpato P, Dattoli GM, Mattioli PL, Mancini M: A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986;77:157-164.
54. Deusch E, Gamsjager T, Kress HG, Kozek-Langenecker SA: Binding of hydroxyethyl starch molecules to the platelet surface. Anesth Analg 2003;97:680-683.
55. Gawaz MP, Dobos G, Spath M, Schollmeyer P, Gurland HJ, Mujais SK: Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994;5:36-46.
56. Brass LF: Thrombin and platelet activation. Chest 2003;124:18S-25S.
57. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-207.
58. Gabbeta J, Yang X, Kowalska MA, Sun L, Dhanasekaran N, Rao AK: Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses. Proc Natl Acad Sci U S A 1997;94:8750-8755.
59. Patel YM, Patel K, Rahman S, Smith MP, Spooner G, Sumathipala R, Mitchell M, Flynn G, Aitken A, Savidge G: Evidence for a role for Galphai1 in mediating weak agonist-induced platelet aggregation in human platelets: reduced Galphai1 expression and defective Gi signaling in the platelets of a patient with a chronic bleeding disorder. Blood 2003;101:4828-4835.
60. Lee SB, Rao AK, Lee KH, Yang X, Bae YS, Rhee SG: Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function. Blood 1996;88:1684-1691.
61. Sun L, Mao G, Rao AK: Association of CBFA2 mutation with decreased platelet PKC-theta and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. Blood 2004;103:948-954.
62. Lages B, Weiss HJ: Impairment of phosphatidylinositol metabolism in a patient with a bleeding disorder associated with defects of initial platelet responses. Thromb Haemost 1988;59:175-179.
63. Lagarde M, Byron PA, Vargaftig BB, Dechavanne M: Impairment of platelet thromboxane A2 generation and of the platelet release reaction in two patients with congenital deficiency of platelet cyclooxygenase. Br J Haematol 1978;38:251-266.
64. Mestel F, Oetliker O, Beck E, Felix R, Imbach P, Wagner HP: Severe bleeding associated with defective thromboxane synthetase. Lancet 1980;i:157.
65. Vlachoyannis J, Schoeppe W: Adenylate cyclase activity and cAMP content of human platelets in uraemia. Eur J Clin Invest 1982;12:379-381.
66. Remuzzi G, Marchesi D, Livio M, Cavenaghi AE, Mecca G, Donati MB, de Gaetano G: Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thromb Res 1978;13:1007-1015.
67. Schwarz UR, Walter U, Eigenthaler M: Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001;62:1153-1161.
68. Brunini TM, Yaqoob MM, Novaes Malagris LE, Ellory JC, Mann GE, Mendes Ribeiro AC: Increased nitric oxide synthesis in uraemic platelets is dependent on L-arginine transport via system y(+)L. Pflugers Arch 2003;445:547-550.
69. Okuma M, Uchino H: Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 1979;54:1258-1271.
70. Amrein PC, Ellman L, Harris WH: Aspirin-induced prolongation of bleeding time and perioperative blood loss. JAMA 1981;245:1825-1828.
71. Moncada S, Vane JR: Mode of action of aspirin-like drugs. Adv Intern Med 1979;24:1-22.
72. Cowan DH: Effect of alcoholism on hemostasis. Semin Hematol 1980;17:137-147.
73. Dyerberg J, Bang HO: Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979;ii:433-435.
74. Siess W, Roth P, Scherer B, Kurzmann I, Bohlig B, Weber PC: Platelet-membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet. Lancet 1980;i:441-444.
75. Gachet C: Identification, characterization, and inhibition of the platelet ADP receptors. Int J Hematol 2001;74:375-381.
76. Oury C, Lenaerts T, Peerlinck K, Vermylen J, Hoylaerts MF: Congenital deficiency of the phospholipase C coupled platelet P2Y1 receptor leads to mild bleeding disorder. Thromb Haemost 1999;85(suppl):20.
77. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden A: An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest 1995;95:1612-1622.
78. Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, Ruggeri ZM: Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A 2003;100:1978-1983.
79. Cattaneo M: Disorders of platelet function. Abnormalities of the platelet P2 receptors. Pathophysiol Haemost Thromb 2006;35:10-14.
80. Reed GL: Platelet secretory mechanisms. Semin Thromb Hemost 2004;30:441-450.
81. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, Clemetson KJ, Alberio L: Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002;415:175-179.
82. Huebsch LB, Harker LA: Disorders of platelet function: mechanisms, diagnosis and management. West J Med 1981;134:109-127.
83. Fuse I: Disorders of platelet function. Crit Rev Oncol Hematol 1996;22:1-25.
84. Kehrel B, Flicker E, Wigbels B, Osterfeld M, van de LJ, Luscher EF: Thrombospondin measured in whole blood - an indicator of platelet activation. Blood Coagul Fibrinolysis 1996;7:202-205.
85. Singbartl K, Forlow SB, Ley K: Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J 2001;15:2337-2344.
86. Furie B, Furie BC, Flaumenhaft R: A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001;86:214-221.
87. Nurden AT, Nurden P: The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 2006;DOI10.1016/j.blre.2005.12.003
88. Lo B, Li L, Gissen P, Christensen H, McKiernan PJ, Ye C, Abdelhaleem M, Hayes JA, Williams MD, Chitayat D, Kahr WH: Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet alpha-granule biogenesis. Blood 2005;106:4159-4166.
89. Kahr WH, Zheng S, Sheth PM, Pai M, Cowie A, Bouchard M, Podor TJ, Rivard GE, Hayward CP: Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001;98:257-265.
90. Francis JL: Platelet dysfunction detected at high shear in patients with heart valve disease. Platelets 2000;11:133-136.
91. Monroe DM, Hoffman M, Roberts HR: Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-1389.
92. Zwaal RF, Schroit AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997;89:1121-1132.
93. Dörmann D, Kardoeus J, Zimmermann RE. Flow-cytometric analysis of agonist-induced annexin V, factor Va and factor Xa binding to human platelets. Platelets 1998;9:171-177.
94. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ: Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989;264:17049-17057.
95. Nesheim ME, Furmaniak-Kazmierczak E, Henin C, Cote G: On the existence of platelet receptors for factor V(a) and factor VIII(a). Thromb Haemost 1993;70:80-86.
96. Bouchard BA, Silveira JR, Tracy PB: On the role of EPR-1 or an EPR-1-like molecule in regulating factor Xa incorporation into platelet prothrombinase. Thromb Haemost 2001;86:1133-1135.
97. Yun TH, Baglia FA, Myles T, Navaneetham D, Lopez JA, Walsh PN, Leung LL: Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem 2003;278:48112-48119.
98. Oliver JA, Monroe DM, Roberts HR, Hoffman M: Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol 1999;19:170-177.
99. Scandura JM, Walsh PN: Factor X bound to the surface of activated human platelets is preferentially activated by platelet-bound factor IXa. Biochemistry 1996;35:8903-8913.
100. Dormann D, Clemetson KJ, Kehrel BE: The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000;96:2469-2478.
101. Brass LF: More pieces of the platelet activation puzzle slide into place. J Clin Invest 1999;104:1663-1665.
102. Zwaal RF, Comfurius P, Bevers EM: Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004;1636:119-128.
103. Stormorken H, Holmsen H, Sund R, Sakariassen KS, Hovig T, Jellum E, Solum O: Studies on the haemostatic defect in a complicated syndrome. An inverse Scott syndrome platelet membrane abnormality? Thromb Haemost 1995;74:1244-1251.
104. Osdoit S, Rosa JP: Fibrin clot retraction by human platelets correlates with alpha(IIb)beta(3) integrin-dependent protein tyrosine dephosphorylation. J Biol Chem 2001;276:6703-6710.
105. McEver RP: Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001;86:746-756.
106. Ogura H, Kawasaki T, Tanaka H, Koh T, Tanaka R, Ozeki Y, Hosotsubo H, Kuwagata Y, Shimazu T, Sugimoto H: Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001;50:801-809.
107. Garlichs CD, Kozina S, Fateh-Moghadam S, Handschu R, Tomandl B, Stumpf C, Eskafi S, Raaz D, Schmeisser A, Yilmaz A, Ludwig J, Neundorfer B, Daniel WG: Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003;34:1412-1418.
108. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL III, Goldberg RJ, Michelson AD: Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002-1006.
109. Tschoepe D, Rauch U, Schwippert B: Platelet-leukocyte-cross-talk in diabetes mellitus. Horm Metab Res 1997;29:631-635.
110. Pitchford SC, Yano H, Lever R, Riffo-Vasquez Y, Ciferri S, Rose MJ, Giannini S, Momi S, Spina D, O'Connor B, Gresele P, Page CP: Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol 2003;112:109-118.
111. Zhao L, Bath P, Losche W, Heptinstall S: Platelet-monocyte interaction and GPIIb/IIIa blockade. Thromb Haemost 2004;92:888-890.
112. Gawaz M, Dickfeld T, Bogner C, Fateh-Moghadam S, Neumann FJ: Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997;23:379-385.
113. Holme PA, Orvim U, Hamers MJ, Solum NO, Brosstad FR, Barstad RM, Sakariassen KS: Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997;17:646-653.
114. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, ten Have K, Eijsman L, Hack CE, Sturk A: Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997;96:3534-3541.
115. Sakariassen KS, Holme PA, Orvim U, Barstad RM, Solum NO, Brosstad FR: Shear-induced platelet activation and platelet microparticle formation in native human blood. Thromb Res 1998;92:S33-S41.
116. Peterson P, Hayes TE, Arkin CF, Bovill EG, Fairweather RB, Rock WA Jr, Triplett DA, Brandt JT: The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998;133:134-139.
117. Savion N, Varon D: Impact - the cone and plate (let) analyzer: testing platelet function and anti-platelet drug response. Pathophysiol Haemost Thromb 2006;35:83-88.
118. Boccardo P, Remuzzi G, Galbusera M: Platelet dysfunction in renal failure. Semin Thromb Hemost 2004;30:579-589.
119. Hassan AA, Kroll MH: Acquired disorders of platelet function. Hematology (Am Soc Hematol Educ Program) 2005;403-408.
120. Mannucci PM: Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A 1995;92:2428-2432.
121. Liesner RJ, Machin SJ: ABC of clinical haematology. Platelet disorders. Br Med J 1997;314:809-812.
122. Macaulay IC, Carr P, Gusnanto A, Ouwehand WH, Fitzgerald D, Watkins NA: Platelet genomics and proteomics in human health and disease. J Clin Invest 2005;115:3370-3377.
123. Dittrich M, Birschmann I, Pfrang J, Herterich S, Smolenski A, Walter U, Dandekar T: Analysis of SAGE data in human platelets: features of the transcriptome in an anucleate cell. Thromb Haemost 2006;95:643-651.
124. Lahav J, Jurk K, Hess O, Barnes MJ, Farndale RW, Luboshitz J, Kehrel BE: Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 2002;100:2472-2478.
125. Ahrens I, Schwarz M, Peter K, Bode C: Therapeutic inhibitors of platelet aggregation - from aspirin to integrin blockers. Transfusion Med Hemother 2007;DOI 10.1159/000097664.